The Hidden Biology Of RNA Impurities: When Manufacturing Changes Therapeutic Behavior
By Jyotsna Jajula, research assistant, Wayne State University

Two mRNA batches may contain the same intended therapeutic sequence yet produce different biological responses. One explanation lies in the unintended RNA species generated during manufacturing.
In vitro transcription (IVT) can produce truncated transcripts, incompletely processed RNA, and double-stranded RNA (dsRNA) byproducts. These impurities differ in molecular structure and potential biological activity. Some can reduce the proportion of functional RNA available for translation, while others can activate innate immune pathways and influence inflammatory responses.1,2
For RNA therapeutic developers, the distinction is consequential. An impurity measurement establishes what is present, but it does not necessarily explain how the material will behave in a biological system.
Recent studies are providing a more detailed understanding of this relationship. By linking transcription conditions, impurity characterization, and functional outcomes, researchers are revealing how manufacturing choices can influence RNA therapeutic performance, and how those findings can inform process development.
When Polymerase Choice Changes RNA Biology
T7 RNA polymerase is widely used in IVT-based mRNA manufacturing. Although different polymerase variants can produce the same intended transcript, they may generate distinct populations of unintended RNA species.
In a 2024 Analytical Chemistry study, Camperi and colleagues at Genentech compared mRNA manufactured using wild-type T7 RNA polymerase and four engineered variants. The researchers characterized RNA integrity, purity, and functional activity, identifying impurities that included abortive transcripts, partial poly(A)-tail species, and dsRNA byproducts.1
The study went beyond conventional impurity quantification. Using mass photometry, the investigators examined higher-molecular-weight RNA species and differences in sense–antisense dsRNA populations. Native mass spectrometry provided further resolution of short 3′-loopback dsRNA byproducts.
Importantly, these analytical differences were connected with cellular measurements. The researchers investigated protein expression and immunological reactogenicity, including responses in bone marrow-derived dendritic cells.1
The findings demonstrate why RNA purity cannot always be represented adequately by a single measurement. Polymerase selection may affect several molecular attributes simultaneously, and different analytical methods can reveal distinct aspects of the resulting RNA population.
This has direct implications for process optimization. A manufacturing modification that improves full-length transcript yield may also change dsRNA composition or other impurity populations. Evaluating only the intended transcript could therefore overlook potentially relevant changes in the final material.
For developers, the more informative question is which molecular species have changed, and whether those changes are associated with functional consequences.
Why Impurity Identity Matters
Not all RNA impurities influence therapeutic performance through the same mechanism.
Truncated or incompletely processed transcripts may affect the proportion of translation-competent RNA. Certain dsRNA species, meanwhile, can engage cellular RNA-sensing pathways and contribute to inflammatory signaling or reduced protein expression.1,2
These mechanisms can produce overlapping experimental outcomes, making interpretation challenging. For example, reduced protein expression may result from impaired transcript integrity, altered translation efficiency, or innate immune activation. Measuring protein expression alone may not identify the underlying cause. Similarly, a dsRNA measurement establishes the presence of material detected by a particular assay but does not necessarily describe its complete structural composition or predict the magnitude of a biological response.
This distinction makes orthogonal analytical characterization particularly valuable. Chromatographic and electrophoretic methods can assess RNA integrity and heterogeneity, while complementary approaches such as mass photometry and native mass spectrometry can provide information about molecular populations that may not be fully resolved by conventional methods.1
Functional assays provide another dimension by examining whether analytical differences correspond to changes in cellular behavior.
The objective is not to characterize every impurity with every available technique. Rather, analytical methods and biological endpoints should be selected according to the quality attributes and potential risks relevant to the intended RNA product.
That approach makes impurity characterization more useful for development decisions without treating every detectable molecular difference as equally consequential.
When The Same Impurity Produces Different Biological Outcomes
The relationship between dsRNA contamination and therapeutic performance becomes especially complex in mRNA vaccines, where antigen expression and immune activation must work together.
A study published in the Journal of Controlled Release in 2026 by Jo and colleagues examined how dsRNA concentration influenced two experimental vaccine systems: influenza hemagglutinin (HA), representing a preventive vaccine, and human papillomavirus (HPV) E7, representing a therapeutic cancer vaccine.2
The researchers investigated mRNA preparations containing different dsRNA concentrations, including experiments involving uridine- and N1-methylpseudouridine-containing transcripts.
In mouse experiments, higher dsRNA concentrations reduced antigen expression and increased proinflammatory cytokine production. However, the consequences for adaptive immunity differed between the vaccine models.
For the influenza HA vaccine, elevated dsRNA levels were associated with reduced antibody titers and impaired T-cell responses. In the HPV E7 model, moderate dsRNA concentrations enhanced CD8-positive T-cell responses under the experimental conditions, whereas higher concentrations were suppressive.2
This contrast illustrates a critical distinction between immune stimulation and productive therapeutic immunity.
A stronger inflammatory response does not necessarily produce a better vaccine response. The effects of inflammatory stimulation depend on the antigen, the magnitude of stimulation, and the biological outcome the vaccine is intended to achieve.
The investigators also identified differences in RNA sequence characteristics and dsRNA generation between the constructs, reinforcing the relationship between transcript design, manufacturing-derived impurities, and immunological behavior.
These findings should not be interpreted as justification for retaining dsRNA impurities in clinical products or relaxing established controls. The observations were generated in defined experimental systems and do not establish clinical impurity acceptance limits.
Instead, they show why impurity-related biological effects require interpretation within the intended therapeutic context.
For developers, the implication is that analytical impurity levels and functional endpoints provide complementary information. Neither should be assumed to fully predict the other.
Reducing Impurities Before They Form
Understanding how RNA impurities arise creates opportunities to control their generation rather than relying exclusively on downstream removal.
In a 2025 Nucleic Acids Research study, Sanjeev and colleagues investigated a chimeric T7 RNA polymerase engineered by attaching a DNA-binding domain to the enzyme. The modification was designed to improve interaction with DNA templates and reduce unintended dsRNA formation during IVT.3
Under the reported experimental conditions, the engineered polymerase reduced dsRNA generation by approximately three- to fourfold compared with wild-type T7 RNA polymerase.
The investigators also observed improved salt tolerance, demonstrating that polymerase design and reaction conditions could be used together to influence transcription performance and impurity formation.
Crucially, the researchers evaluated more than analytical purity. The mRNA generated using the engineered polymerase retained translation activity and showed reduced immune stimulation in the tested in vitro systems.3
This provides a useful example of connecting an upstream process intervention with measurable changes in both RNA quality and biological behavior.
For manufacturing development, the significance extends beyond a particular polymerase design. It demonstrates how understanding impurity formation mechanisms can guide process engineering.
However, the reported performance cannot be assumed to extend unchanged across different RNA sequences, manufacturing scales, or therapeutic applications. Product-specific evaluation remains necessary.
The broader opportunity is to consider impurity prevention and downstream purification as complementary components of an integrated control strategy.
Translating Impurity Data Into Manufacturing Decisions
The practical value of impurity research becomes clearer when analytical findings are connected to decisions about process selection, optimization, and comparability.
Consider a change in IVT conditions that reduces measured dsRNA content while maintaining RNA yield. The result may appear favorable, but an effective assessment requires more than comparing impurity percentages.
Developers need to understand whether the modification changes other relevant RNA attributes, whether the reduction is reproducible, and whether the resulting material maintains the intended biological activity.
Three questions can help structure that assessment:
- What changed analytically? Establish differences in RNA integrity, impurity abundance, and relevant molecular characteristics using suitable analytical methods.
- What changed functionally? Determine whether the modified material shows differences in relevant biological endpoints, such as protein expression, innate immune activation, or target-cell function.
- What does the evidence mean for the process? Assess whether the observed changes support the intended quality profile and whether additional investigation is needed before adopting the modification.
These questions are especially relevant when evaluating manufacturing changes that affect multiple critical quality attributes (CQAs).
The appropriate functional endpoints will depend on the product. For an mRNA protein-replacement therapy, expression magnitude and duration may be particularly informative. For an mRNA vaccine, antigen expression and relevant immune responses may both require consideration. In RNA-based cell engineering, target-cell viability and functional activity may provide additional evidence.
Importantly, biological testing does not replace established analytical controls, validated methods, or product-specific specifications. Nor does a favorable functional result automatically demonstrate that a manufacturing change is acceptable.
Instead, linking analytical and functional evidence can strengthen process understanding, support risk-based investigations, and provide a more scientifically grounded basis for evaluating manufacturing comparability.
The aim is not simply to produce a cleaner analytical profile. It is to understand whether the process consistently generates RNA with the quality attributes required for its intended therapeutic function.
The Next Frontier In RNA Quality
RNA manufacturing has advanced considerably in controlling transcript integrity and removing unwanted species. Recent research is adding another dimension: a clearer understanding of how specific impurities arise and influence biological performance.
The studies discussed here demonstrate three complementary developments. Polymerase selection can alter the composition of RNA impurity populations. Biological responses associated with dsRNA can differ across vaccine applications. And upstream enzyme engineering can reduce impurity formation while preserving functional RNA activity.1,3
Together, these findings reinforce the importance of rigorous manufacturing controls while highlighting the value of connecting molecular characterization with biological evidence.
For RNA therapeutic developers, this approach can make analytical results more informative, improve the interpretation of process changes, and support stronger decisions during product development.
The next advance in RNA quality may therefore come not only from detecting smaller amounts of impurities, but from understanding more precisely which molecular differences matter, why they arise, and how they influence the performance of the intended therapeutic product.
References
- Camperi J, et al. (2024). Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses. Analytical Chemistry, 96(44), 17789–17799. doi.org/10.1021/acs.analchem.4c04162
- Jo S, et al. (2026). A systemic evaluation of the effect of dsRNA contamination on mRNA vaccine expression and immunogenicity. Journal of Controlled Release, 389, 114471. doi.org/10.1016/j.jconrel.2025.114471
- Sanjeev A, et al. (2025). Engineered chimeric T7 RNA polymerase improves salt tolerance and reduces dsRNA impurity generation during in vitro transcription of mRNA. Nucleic Acids Research, 53(21), gkaf1124. doi.org/10.1093/nar/gkaf1124
About The Author
Jyotsna Jajula is a research assistant at Wayne State University. Her work broadly explores RNA delivery mechanisms in oncology cell models, with a focus on internalization and cytoplasmic fate of therapeutic peptides. Jajula holds a master’s degree in pharmaceutical sciences and has prior research experience in lipid nanoparticles, RNA stability, and biodistribution strategies across oncology, immunology, and gene-therapy applications.